Overview
- Idexx posted Q3 revenue of about $1.105–$1.11 billion and adjusted EPS of $3.22, topping consensus estimates.
- The company raised full-year guidance to $12.81–$13.01 in EPS and $4.27–$4.30 billion in sales, with higher expected growth in recurring diagnostics revenue.
- Companion Animal Group and Livestock/Poultry/Dairy led double-digit growth, including faster international CAG gains, while Water also advanced.
- Profitability improved as gross margin rose to 61.8% and operating margin reached 32.1%, supported by lab productivity, consumables growth and pricing.
- Shares jumped as much as 16% to record highs, with analysts highlighting new products such as InVue Dx and Cancer Dx, instrument placements and overseas traction as key watch items.